Browse studies

Find your next paid study

1 recruiting study matching your filters

Targeted Therapy With the IDH2-Inhibitor Enasidenib (AG221) for High-Risk IDH2-Mutant Myelodysplastic Syndrome

This phase II trial studies the side effects and how well azacitidine and enasidenib work in treating patients with IDH2-mutant myelodysplastic syndrome. Azaci…

Acute Myeloid LeukemiaBlasts 20-30 Percent of Bone Marrow Nucleated CellsChronic Myelomonocytic Leukemia+4 more

M.D. Anderson Cancer CenterNCT03383575